Navigation Links
Exelixis to Receive Milestone Payment From Bristol-Myers Squibb for Achievement of Liver X Receptor Agonist Development Milestone
Date:11/29/2007

SOUTH SAN FRANCISCO, Calif., Nov. 29 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) today announced that its right to receive from Bristol-Myers Squibb (NYSE: BMY) a milestone payment of $5 million was triggered as a result of the acceptance of an Investigational New Drug application, or foreign equivalent, for a compound discovered and developed under the two companies' Liver X Receptor (LXR) collaboration.

This is the first clinical trial of a compound in this collaboration to discover novel therapies targeted against LXR, a nuclear hormone receptor implicated in a variety of cardiovascular and metabolic disorders. "The quality of our lead candidate and the speed at which it progressed into the clinic are testaments to the efficiency of our LXR collaboration with Bristol-Myers Squibb," said Michael Morrissey, Ph.D., Exelixis' president of research and development. "Our combined preclinical studies suggest that LXR agonists may have significant potential in treating a number of cardiovascular and metabolic disorders including atherosclerosis, and we look forward to Bristol-Myers Squibb's further investigating that potential in this trial."

Exelixis and Bristol-Myers Squibb established their joint LXR collaboration in January 2006 for an initial period of two years. The collaboration calls for Exelixis and Bristol-Myers Squibb to jointly identify drug candidates that are ready for IND-enabling studies, with Bristol-Myers Squibb then undertaking further preclinical development. Bristol-Myers Squibb also has responsibility for clinical development, regulatory, manufacturing and sales/marketing activities for such compounds. At time of signing, Exelixis received a $17.5 million upfront payment and a commitment from Bristol-Myers Squibb to provide R&D funding of approximately $10 million per year for the initial two year period. Exelixis may also receive pre-specified development and regulatory milestones totaling approximately $140 million per product for up to two products from the collaboration, as well as sales milestones and royalties on sales of products commercialized under the collaboration.

In September 2007, Exelixis announced that the collaboration had been extended through January 12, 2009. Terms of the extension include additional research funding paid to Exelixis in the amount of $7.5 million. Bristol-Myers Squibb also has an option to further extend the collaboration by an additional year.

About the Liver X Receptor

LXR activation by endogenous ligands, oxysterols (oxidized cholesterol) or by synthetic agonists, initiates a cascade of cellular events that both increase "reverse cholesterol transport," thereby removing excess cholesterol from the body, and suppress inflammation. Elevated cholesterol concentrations have been implicated in the progression of heart disease and plaque formation in the artery wall. LXR activation therefore directly targets two well-known risk factors of heart disease and provides a novel approach for decreasing the deposition of fat and lipids in the artery wall and suppressing the inflammatory damage associated with atherosclerosis. In animal models of heart disease, small molecule synthetic LXR ligands have been shown to cause regression of pre-existing atherosclerotic lesions. Thus, LXR may be a first-in-class target for therapies that directly target the pathology of atherosclerosis and coronary artery disease via a dual mechanism of stimulating reverse cholesterol transport and repression of inflammation.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.

Exelixis' Forward Looking Language Statements

This press release contains forward-looking statements, including, without limitation, all statements related to the potential efficacy of the compound targeted against LXR, the discovery, development and commercialization of additional drug candidates targeting LXR under Exelixis' collaboration with Bristol-Myers Squibb and related costs and payments under the collaboration. Words such as "suggest," "may," "look forward" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Exelixis' current expectations. Forward-looking statements involve risks and uncertainties and past performance is not indicative of future results. Exelixis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risk that products candidates that appeared promising in early research do not demonstrate safety or efficacy in clinical trials; the ability of Exelixis to advance preclinical compounds into clinical development; the uncertainty of the U.S. Food and Drug Administration approval process; and the therapeutic and commercial value of Exelixis' compounds and risks related to its need for additional financing. These and other risk factors are discussed under "Risk Factors" and elsewhere in Exelixis' quarterly report on Form 10-Q for the quarter ended September 30, 2007 and other filings with the Securities and Exchange Commission. Exelixis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Exelixis' expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.


'/>"/>
SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Exelixis Commences Public Offering of Common Stock
2. Exelixis Announces September 18 Webcast of Presentation at the Bank of America 2007 Investment Conference
3. Exelixis Announces October 10 Webcast of Presentation at the 2007 Bio InvestorForum Conference
4. Exelixis Announces November 6 Webcast of Presentation at the CIBC World Markets 18th Annual Healthcare Conference
5. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
6. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
7. DaVita Receives Civil Complaint
8. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
9. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
10. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
11. Mayo Clinic Multidisciplinary Simulation Center Receives Distinction as an ACS-Accredited Education Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... Durham, NC (PRWEB) , ... March 30, 2017 ... ... professionals, will host the live audio conference “ Preventing Hospital Readmissions Through Discharge ... April 12, 2017 at 1:00 pm ET. This conference discusses strategies to prevent ...
(Date:3/29/2017)... ... March 29, 2017 , ... In the United States alone, up ... year develop other types of metastatic brain tumors(3). Though most meningiomas are benign, metastatic ... focus on finding more effective treatment options, the San Diego Gamma Knife Center ...
(Date:3/29/2017)... ... March 30, 2017 , ... CHARM CITY RUN WELCOMES MERCY MEDICAL CENTER AS ... Medical Center will serve as the official title sponsor of the Baltimore Women’s Classic, ... 2017, thousands of women will walk or run the course around the Baltimore Inner ...
(Date:3/29/2017)... ... March 29, 2017 , ... Wells Pharmacy ... attending prescribers at the upcoming World Congress, in Hollywood Florida April 6-8, 2017. ... recognized as the visionary leader in the training of physicians, scientists, and members ...
(Date:3/29/2017)... ... 29, 2017 , ... Patients interested in receiving quick and ... Jamie Cameron, with or without a referral. The FASTBRACES system is valued for ... each patient’s case, treatment with the FASTBRACES system could be completed in 120 ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... DUBLIN , Mar. 29, 2017 ... "Intraoperative Neuromonitoring (IONM) Market Size & Forecast By Type (Insource ... - 2025" report to their offering. ... The global Intraoperative ... by 2025. The intraoperative neuromonitoring market is anticipated to witness ...
(Date:3/29/2017)... March 29, 2017 Global intravenous (IV) iron and ... by 2021, growing at a CAGR of 5%. ... a doctor to treat anemia or other iron deficiencies. Oral ... the body. However, in some cases, oral administrations are not ... intravenous (IV) iron therapy comes into the picture. ...
(Date:3/29/2017)... 29, 2017 Today, CVS Health officials (NYSE: ... , Department of Public Health Director Gerd Clabaugh ... in announcing the availability of the opioid overdose-reversal medicine ... Iowa.  CVS Health has established a standing order with physicians ... to expand access to the medication in the state.   ...
Breaking Medicine Technology: